Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- DKK | -.--% | -.--% | -.--% |
07-02 | Tesla, megacaps drive S&P 500, Nasdaq higher; rates outlook in focus | RE |
07-02 | Novo Nordisk, Eli Lilly Charging 'Unconscionably' High Prices, Biden, Sanders Say | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.3 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 641B | - | ||
+55.55% | 823B | C+ | ||
-6.83% | 352B | C+ | ||
+17.15% | 324B | B- | ||
+7.09% | 301B | C+ | ||
+14.02% | 241B | B+ | ||
+1.64% | 223B | A+ | ||
+13.66% | 218B | B- | ||
+7.87% | 167B | C+ | ||
-3.33% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVO B Stock
- 0QIU Stock
- Ratings Novo Nordisk AS